Advancell

Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects

Advancell has announced the initiation of a clinical phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy. This treatment could be available on the market by the end of 2015 or beginning of 2016

Advancell Announces Positive Phase I/IIa Results With Acadra (Acadesine) in Chronic Lymphocytic Leukemia - CLL

BARCELONA, July 19, 2011 - • NT-KO-003, developed by Advancell and Neurotec Pharma, is the first MS drug with neuroprotective effects that does not cause immunosuppression.

MORE..

BARCELONA, April 20, 2011 - ADVANCELL (www.advancell.net/), an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

MORE..

Older News

BARCELONA, Spain, February 21, 2011 - ADVANCELL (www.advancell.net/), an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia (www.cancer.gov/) (CLL) patients resistant to current therapies.

MORE..